MaSTherCell S.A.’s lease agreement for a 5,700m2 (61,354ft²) facility in Belgium will expands its European manufacturing capacity for late-stage and commercially-approved cell and gene therapy products.
GOSSELIES, BELGIUM – March 26, 2019 – MaSTherCell S.A. a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated Contract Development and Manufacturing Organization (CDMO) announces that it has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021.
This new site will significantly expand MaSTherCell’s current European manufacturing capacity. MaSTherCell will continue to use its existing site for both industrialization and early to mid-stage clinical programs.
The facility will include industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide the cell and gene therapy community a lean solution for giving its partners a competitive advantage.
“As a leading CDMO, MaSTherCell has a role to play in solving the current lack of commercial manufacturing capacities in Europe and we believe this facility will be a game changer for market access worldwide,” said Dr. Denis Bedoret, CEO of MaSTherCell SA and President of Masthercell Global. “With this new site, we aim to be the first CDMO in Europe to have a dedicated area for large-scale commercial manufacturing.”
“It was natural for us to set up this state-of-the-art plant in the Gosselies Biopark. Not only will we remain close to our current site and centre of excellence, but also because operating in this world-leading biotechnology cluster will enable us to benefit from a first-class environment in terms of skills, people and know-how.
This new production plant will create several hundred jobs and in addition to being able to count on Belgian expertise to train our teams, being in the heart of Europe will undoubtedly be very attractive for our international recruitment,” said Eric Mathieu, Chief of Operations of MaStherCell SA.
Source: MaStherCell SA (PDF)
To learn about other market competitors to MaStherCell SA, view BioInformant’s “Database of Cell and Gene Therapy CMOs / CDMOs.”
